Tirzepatide Microdose

What it is

Tirzepatide is a dual GIP and GLP-1 receptor agonist, a 39-amino-acid modified peptide that activates both incretin receptor pathways rather than one alone. It enhances first- and second-phase insulin secretion in a glucose-dependent manner and reduces glucagon levels, effects documented in the clinical pharmacology of its FDA-approved brand versions (MOUNJARO (tirzepatide) FDA label). Mounjaro is FDA approved for glycemic control in type 2 diabetes and Zepbound is FDA approved for chronic weight management; compounded tirzepatide, the form available through this telehealth pathway, is not FDA approved, and only those two brand products carry that status for their specific indications.

This microdose option is a lower entry dose intended as a starter dose for patients whose provider determines a reduced dose is the appropriate starting point, typically to support gradual titration and tolerability rather than as a patient-selected discount tier. Tirzepatide, at any dose, is available after a licensed-provider evaluation and, if prescribed, is compounded through a US-licensed compounding pharmacy.

Van Peptides connects patients with an independent network of US-licensed providers who evaluate whether tirzepatide, and at what starting dose, fits your history and goals. We do not diagnose, prescribe, or dispense, and we do not employ the providers or the pharmacy.

What the literature has explored

Mounjaro and Zepbound’s approved labeling documents that tirzepatide lowers fasting and postprandial glucose and reduces body weight in studied populations, effects attributed to its dual action on GIP and GLP-1 receptors (MOUNJARO FDA label). Their approved dosing schedules use a defined escalation, starting at a low dose and increasing at intervals, a design intended to reduce gastrointestinal side effects while the body adjusts to dual-incretin-receptor activation.

That same titration logic, a lower starting dose to support tolerability before any increase, is the clinical reasoning some providers apply when considering a reduced entry dose for compounded tirzepatide, though the compounded dosing options here have not been studied in the same trial framework as Mounjaro or Zepbound. Outcomes are individual, and a lower entry dose is not presented as equivalent to, or a substitute for, the specific FDA-reviewed schedules of the approved brand products.

We describe the approved brand-drug facts because they represent the most rigorous data available on this molecule’s mechanism and dosing logic, but we do not claim compounded tirzepatide, at a microdose or otherwise, carries the same FDA approval or produces the same measured results.